Paul J. Hergenrother,Elizabeth I. Parkinson,Joseph S. Bair
申请号：
US15126786
公开号：
US09920069B2
申请日:
2015.03.17
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.
